Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

NuVasive Riding A New Wave Of Optimism

Sell-side analysts still seem to be nervous about the near-term future of the spine market, but investors haven't let that scare them away from NuVasive (NASDAQ:NUVA). With new products and a focused OUS strategy re-accelerating growth and management laying out some bold ambitions for the next five years, these shares have more than doubled over the past year. This move doesn't have the shares looking particularly cheap these days, but if expectations for ortho M&A stay in place and NuVasive continues to take share from large rivals like Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT), I don't think the Street will get all that concerned about valuation.

Turbulence In The Spine Market Isn't Going...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details